Effect of exogenous ANP on initial renal function following 24-hour cold preservation  by Lewis, Richard et al.
Kidney International, Vol. 36 (1989), PP. 562—569
Effect of exogenous ANP on initial renal function following
24-hour cold preservation
RICHARD LEWIS, ROBERT JANNEY, RICHARD OSGOOD, JAMES MCANDREW, REGINA VERANI,
and TERRANCE FRIED
Divisions of Urology and Organ Transplantation/Immunology, Department of Surgery, The University of Texas Health Science Center at
Houston, Houston, and Renal Division, Department of Medicine, The University of Texas Health Science Center at San Antonio, San
Antonio, Texas, USA
Effect of exogenous ANP on initial renal function following 24-hour cold
preservation. The impact of synthetic atrial natriuretic peptide (sANP)
on renal function following cold ischemic injury was studied in a canine
autotransplant model. Following a prenephrectomy inulin clearance
determination (C1,,), the left kidney was excised, flushed with Eurocol-
lins solution, and cold-stored for 24 hours. Immediately following
reperfusion and a 10 minute equilibration period, baseline C1,, was
measured over a 20-minute time interval (Collection Period I). Exper-
imental animals (N = 11) then received I mcg/kg sANP by intravenous
bolus followed by a continuous infusion at 0.3 mcg/kg/min for 30
minutes, C1,, was measured throughout the infusion (Collection Period
II). Normal saline was substituted for sANP in control animals (N =
11). Ci,, was also measured 24 hours following reimplantation in seven
control and seven sANP-treated animals. Autograft inulin clearance
increased from 0.32 0.11 mllmin during Period Ito 2.5 0.6 mI/mm
during sANP infusion (P < 0.01). This increase in C1,, associated with
ANP infusion was accompanied by increases in urine flow rate (V) (0.15
0.05 mI/mm to 0.98 0.21 mI/mm, P < 0.01) and renal blood flow
(RBF) measured by electromagnetic flow probe (85 17 mI/mm to 171
13 mI/mm, P < 0.05). No significant changes in C1,,, V, or RBF
occurred in control animals between periods I and 11. Although sys-
temic blood pressure declined during sANP infusion, it did not decrease
to an extent that compromised peripheral perfusion. C1,, determined 24
hours after autograft reimplantation in the ANP-treated animals approx-
imated or exceeded values determined during ANP infusion (Period II).
In summary, systemic administration of sANP 30 minutes following
reperfusion of canine renal autografts significantly improved immediate
renal autograft function following 24 hours of cold preservation. The
beneficial impact of sANP on immediate autograft function was sus-
tained 24 hours following administration. These observations suggest
that the protective effect of sANP derives from prevention or amelio-
ration of pathophysiologic events initiated at the time of reperfusion.
The rate and degree of return of cadaveric renal allograft
function in the immediate post-transplant period is generally
recognized as one of the most important determinants of
long-term graft survival 11, 21. Initial dysfunction of renal
allografts occurs primarily as a consequence of ischemic injury
mediated by multiple factors including donor hemodynamic
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instability, extended warm or cold ischemic times, acute immu-
nologic injury, and acute cyclosporine nephrotoxicity [3].
The endogenous, mammalian polypeptide, atrial natriuretic
factor (ANF), was isolated and characterized after deBold et al
demonstrated the potent diuretic and natriuretic effects of atrial
extracts administered intravenously in rats [4]. The direct renal
effects of synthetic atrial natriuretic peptides (5ANP) are dose-
dependent and antagonistic to many of the pathophysiologic
abnormalities mediating initial renal allograft dysfunction [5, 6].
In addition to its effects on salt and water excretion [4, 7], sANP
have been found to increase intrarenal perfusion in states of
established intrarenal vasoconstriction, enhance regional blood
flow in the juxtamedullary area, and directly augment glomer-
ular filtration by increasing capillary permeability and hydro-
static pressure [7—17].
The purpose of the current study was to determine the effects
of systemic administration of supraphysiologic quantities of
sANP on recovery of renal function following cold ischemic
injury in a setting closely analogous to that of clinical transplan-
tation. To eliminate the variables of immunologic and nephro-
toxic injuries, a canine autotransplant model was utilized.
Methods
The experimental protocol is schematically depicted in Fig-
ure 1. Conditioned mongrel dogs weighing 20 to 25 kg were used
in the study. Animals were anesthetized with intravenous
sodium pentobarbitol (30 mg/kg) with additional doses given as
needed to maintain anesthesia. Endotracheal intubation was
performed and the animals ventilated with a Metomatic respi-
rator (Ohio Medical Products, Atlanta, Georgia, USA).
A single cannula was placed in the peripheral vein of the
foreleg and a double-lumen cannula with offset ends inserted in
the external jugular vein and externalized over the scapulae.
After baseline blood specimens were obtained, animals re-
ceived a 50 mg/kg intravenous bolus injection of inulin (Taylor
Pharmaceutical Co. Decatur, Illinois, USA) followed by con-
tinuous infusion of 10% inulin/l ml (0.05 mI/kg/hr diluted in
normal saline) at a rate per mm. Arterial pressure was moni-
tored utilizing an ultrasonic Doppler flow detector (Parks Elec-
tronics Laboratories, Beaverton, Oregon, USA) and sphygmo-
manometer (W.T. Stover Co., Austin, Texas, USA). The left
kidney, ureter, renal artery and renal vein were exposed via a
562
Lewis et a!: Impact on ANP after cold iscflemia
flank incision. The ureter was divided distally and cannulated
with polyethylene tubing. Following equilibration (60 mm
after inulin infusion begun and 30 to 45 minutes following
skeletonization of vessels), three 10-minute inulin clearance
collections were obtained. Renal blood flow was then measured
by an electromagnetic flow probe (Carolina Medical Electron-
ics, King, North Carolina, USA) and animals received 6.25 g of
25% mannitol and 1500 units of heparin intravenously. Five
minutes following the mannitol and heparin infusions, the renal
vessels were divided and ligated. The kidney was then excised,
flushed with Eurocollins solution (Fresenius AG, FRG),
weighed, and cold-stored (Eurocollins) for 24 hours at 0 to 4°C.
The double lumen cannula in the jugular vein was flushed with
heparinized saline and maintained in place post-operatively. To
exclude acute, compensatory mechanisms from impacting on
autograft function following reimplantation [181, the contralat-
eral (right) kidneys remained in situ in all animals throughout
the entire protocol.
Autotranspiantation was performed 24 hours following ne-
phrectomy through a transabdominal, midline incision extended
over the right iliac fossa. Baseline blood specimens were
obtained and a bolus injection of inulin followed by continuous
intravenous infusion as previously described was given. Arte-
rial pressure monitoring during the auto-transplantation was
again done utilizing an ultrasonic Doppler flow detector. The
autograft renal vein was anastamosed end-to-side to the right
external iliac vein and the renal artery anastamosed end-to-end
to the right common iliac artery. Following completion of the
anastamoses and restoration of blood flow to the autograft, the
ureter was cannulated with polyethylene tubing to obtain au-
tograft clearance determinations. Following a 10-minute equil-
ibration period, two, 10-minute inulin clearance collections
were obtained (Period I). Animals received a maintenance
infusion of 10 mI/kg/hr normal saline and I mI/mm of ANF
vehicle (normal saline). Immediately after completion of the
second inulin clearance collection, blood flow to the autograft
was measured.
Following completion of the initial clearance collections and
blood flow determination (that is, 30 mm after restoration of
blood flow to the autograft), animals in the experimental group
received an intravenous bolus of I mcg/kg ahANP (Penninsula
Laboratories, Belmont, California, USA) followed by a contin-
uous intravenous infusion at 0.3 mcg/kglmin for 30 minutes at I
mI/mm. Control animals received normal saline vehicle admin-
istered at the same rate. Three, 10-minute inulin clearance
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Fig. 1. Study protoco!. * Exp. group: ahANP,
1 mcg/kg iv. —* 0.3 mcg/kg/min x 30 mm;
*Control group: normal saline vehicle.
collections were obtained beginning one minute after initiation
of the ahANP (or vehicle) infusion (Period II). Following
completion of the last clearance collection, blood flow to the
kidney was again measured. Blood pressure was recorded at 10
minute intervals throughout all collection periods. Following
completion of the sANP infusion, a cutaneous ureterostomy
was constructed and the operative wound closed. The cannula
was left within the lumen of the exteriorized ureter. As previ-
ously noted, the contralateral (right) kidney was left in place
and the animals were recovered. Twenty-four hours later (48
hours following nephrectomy) three, 10-minute inulin clear-
ances collections were obtained in seven control and seven
ahANP-treated animals. ahANP was administered only during
period II.
Animals were sacrificed following completion of the 48-hour
clearance collections. A specimen of autograft tissue was
obtained for histologic evaluation immediately following eutha-
nasia of the animals studied 24 hours following autotransplan-
tation. A specimen of autograft tissue was obtained for his-
tologic study. After formalin fixation, biopsy specimens were
stained with hematoxlyn and eosin. Semiquantitative histologic
evaluations were performed by one of us (R.V.) without prior
knowledge of whether the specimen was from an experimental
or control subject. Specimens were graded I + to 4+ for tubular
necrosis and cast formation (I + <5%; 2 + 5%—29%; 3 +
30%—50%; and 4 + >50% of tubules counted).
Inulin levels in urine and blood specimens were measured
using an autoanalyzer (Technicon Inst. Corp., Tarrytown, New
York, USA). Clearance determinations were made utilizing the
standard formula, UxV/P. Systolic blood pressures recorded
during the 20 minutes prior to, and 30 minutes of test agent
infusion, were expressed as the mean of values measured at 10
minute intervals during these two periods of time.
Data was analyzed by the MEDLOG Clinical Data Manage-
ment System (Information Analysis Corp., Moutainview, Cali-
fornia, USA). Results are expressed as mean standard error
of the mean (sEM). Data analyses were performed using the
Student's t-test for paired (intragroup) and unpaired (inter-
group) data.
Results
Urine flow rate (V)
Prenephrectomy urine flow rates did not differ between
experimental and control animals (Table 1). ahANP infusion
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Table 1. Autograft function following restoration of blood flow
Time reflow
Inulin clearance
mI/mm
Urine flow rate
mI/mm
Renal blood flow
mI/mm
CON hANP CON ahANP CON ahANP
Prenephrectomya 31.1 2.4 28.0 1.8 1.2 0.2 1.7 0.3 146 14 129 16
P./ Il II 11 11 8 7
Period I 0.44 0.12 0.32 0.11 0.14 0.02 0.15 0.05 59 5 85 17
N Il 11 II II 9 7
Period!! 0.66 0.21 2.5 06bc 0.17 0.04 0.98 021bc 66 II 171 I3'
IV II II 11 II 9 7
24 Hr. 1.2 0.2 3.5 0.8' 0.15 0.05 0.21 0.05e — —
N 7 7 7 7
a Determinations made on experimental (left) kidney prior to excisionb P < .01 vs. ahANP, Period I
P < .01 vs. control, Period Hd P < .05 vs. control, 24 hr
P < .05 vs. ahANP, Period II
E
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Fig. 2. Effect of ANP on urine flow rate p
Period 11 24-hour cold ischemia. A. Control group. B.
(ANP) Experimental group.
produced a prompt and marked diuretic response in experimen-
tal animals, V increasing from 0.15 0.05 mI/mm during Period
Ito 0.98 0.21 mI/mm during period II (P < 0.01; Table 1, Fig.
2). Urine flow rate did not change significantly during Period I
versus Period II in control animals (Table I, Fig. 2). In contrast
to the observations made during Period II, urine flow rate 24
hours following autotransplantation was comparable in control
(N = 7) and ahANP-treated (N = 7) animals (0.15 0.05
mI/mm vs. 0.21 0.05 mI/mm, P = NS; Table I).
mu/in clearance (C1,,) determinations
Prenephrectomy C1,, levels were comparable in the control
and ahANP-treated groups (31.1 2.4 mI/mm vs. 28.0 1.8
mI/mm, respectively, P = NS; Table 1). All kidneys were
cold-stored for 24 hours and surface-cooled with cold saline
during autotransplantation. Anastamotic times did not differ
between control and experimental animals (48 2 mm vs. 52
2 mm, respectively, P NS).
Inulin clearances during Period I were comparable in
ahANP-treated versus control animals (0.32 0.11 mI/mm vs.
0.44 0.12 mI/mm, respectively, P = NS; Table I). While C1,,
did not change significantly between Periods I and II in control
animals (0.44 0.12 mI/mm vs. 0.66 0.21 mI/mm, respec-
tively, P = NS), administration of ahANP during Period II
resulted in a substantial increase in C1,, versus Period 1(2.5
0.6 mI/mm vs. 0.32 0.11 mI/mm, respectively, P < 0.01; Table
I, Fig. 3). The immediate improvement in inulin clearance
observed during ANP administration was associated with in-
creased urine flow rates and urine inulin concentrations which
tended to be greater than Period I values (114 26 mg% vs. 79
14 mg%, respectively, P = 0.08). At 24 hours following
autotranspiantation, inulin clearance was equivalent to or ex-
ceeded Period II levels in all ANP-treated animals (3.5 0.8
mi/mm vs. 2.5 0.6 mI/mm, respectively, P = 0.05; Table 1,
Fig. 4), C1,, at 24 hours following autotranspiantation was also
increased versus Period II levels in the control group (1.2 0.2
mI/mm vs. 0.66 0.21 mI/mm, respectively, P 0.08) but
remained significantly lower than C1,, in ANP-treated animals at
24 hours (P < 0.05; Table I, Fig. 4).
The beneficial effect of sANP on autograft function both
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acutely (Period H) and at 24 hours following autotransplantation
is also apparent when results are analyzed in terms of percent
recovery of prenephrectomy inulin clearance levels (Fig. 5).
Autograft function in the control group during Period II was 2.5
1.0% of prenephrectomy levels versus 3.6 0.6% at 24 hours
(P = 0.07). Experimental animals recovered to 9.6 2.3% of
baseline autograft function during ANP infusion (Period II) (P
< 0.05 vs. controls) and 12.8 3.2% at 24 hours following
autotranspiantation (P < 0.05 vs. Period II). The difference
between ANP-treated and control animals vis-a-vis percent
recovery at 24 hours was also statistically significant (P < 0.05).
Renal and systemic hemodynamics
Baseline renal blood flow (RBF) levels measured prior to
nephrectomy were comparable in the experimental versus
control animals (Table I). A significant increase in RBF oc-
curred during ahANP infusion (Period II; 171 13 mI/mm vs.
85 17 ml/min during Period I, P < 0.01; Table 1, Fig. 6). In
contrast, RBF did not increase appreciably in control animals
between Periods I and 11(59 5 mI/mm vs. 66 11 mI/mm,
respectively, P = NS; Table I, Fig. 6).
Mean systolic blood pressure dropped from 148 7 mm Hg
during Period I to 130 6 mm Hg during ahANP infusion
(Period II; P < 0.01; Fig. 7). Mean systolic blood pressure
during Period II was unchanged from Period I levels in control
animals (148 8 mm Hg vs. 145 7 mm Hg, respectively, P =
NS; Fig. 7).
Histologic data
Although tubular epithelial cell necrosis was present in both
the experimental and control groups, it was less severe in the
ANP-treated animals. Cast formation in each group was, how-
ever, comparable. Mean histologic grading scores for tubular
necrosis were 1.8 0.4 in ahANP-treated (N = 5) vs. 3.3 0.3
in controls (N = 7; P < 0.05). Scores reflecting tubular cast
formation were 1.6 0.4 in the treated animals and 2.1 0.5 in
controls (P = NS).
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Fig. 3. Effect of ANP on inulin clearance j7
Period II 24-hour cold ischernia. A. Control group. B.
(ANP) Experimental group.
Fig. 4. Inulin clearance 24 hours following
auto-transplantation. A. Control group. B.
Experimental group.
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Discussion
Intravenous administration of supraphysiologic quantities of
ahANP markedly enhanced inulin clearance, urine flow rate,
and renal blood flow immediately following reperfusion of
canine renal autografts cold stored for 24 hours. ahANP de-
creased mean systolic pressures but did not significantly com-
promise hemodynamic stability or peripheral perfusion. The
beneficial impact on immediate recovery of autograft function
associated with ahANP treatment of relatively short duration
was sustained at 24 hours in spite of an elimination half-life of2l
5.4 minutes in the dog [191. Thus, the data suggest that the
protective effect of sANP derives from prevention or ameliora-
tion of pathophysiologic changes initiated at the time of reper-
fusion.
Semiquantitative analysis of histologic specimens showed
that ANP-treated animals had less tubular epithelial cell necro-
sis but a comparable degree of tubular cast formation versus
controls. The reason for this discordance between the degree of
necrosis and tubular cast formation is unclear. It is apparent
from studies of warm ischemic injury, however, that histopa-
thology does not correlate consistently with the beneficial effect
of sANP on post-ischemic renal function. Previous studies have
reported a protective effect of sANP in renal artery clamping
models occurring in association with histopathologic changes
that were both comparable to and minimal versus those ob-
served in untreated animals [12, 20].
The promotion of recovery from cold ischemic injury by
sANP observed in the present study is consistent with results of
investigations utilizing warm ischemic models. Intrarenal infu-
sion of sANP has been shown to confer a significant protective
effect from norepinephrine-induced acute renal injury in the rat
[21]. Nakamoto et al [12] studied a renal artery clamping model
in the rat in which administration of sANP was shown to
enhance recovery of renal plasma flow and inulin clearance
following warm ischemic injury. The latter study also demon-
strated a significantly greater rate of regeneration of adenosine
triphosphate in treated versus control animals [121. Enhanced
recovery from warm ischemic injury in the rat has also been
reported by Gianello et al [221 and Cole and Needleman [23].
Similar to the findings reported in the present study with regard
to persistence of the beneficial effect of ANP on recovery from
ischemic injury beyond the period of ANP administration,
Shaw et al [201 found that a four hour, post-ischemic sANP
infusion in rats immediately following renal artery clamp re-
lease was associated with a return of creatinine clearance to
baseline levels both during infusion and at 24 hours. Neumayer
et al [24] also reported a protective effect of sANP administra-
tion on ischemic injury following 120 minutes of renal artery
occlusion in unilaterally nephrectomized, conscious dogs which
was sustained beyond the period of ANP administration.
The present study, as well as the investigations cited above,
differ from the clinical setting in that chronic renal insufficiency
is generally characterized by volume overload and elevated
levels of endogenous ANF [251. It remains to be determined if
the impact of supraphysiologic doses of sANP on recovery from
acute ischemic injury in a model of established chronic renal
insufficiency, associated with high, endogenous ANF levels,
will be comparable to that observed in the present study.
sANP may promote recovery from cold ischemic injury by
multiple mechanisms. Vascular smooth muscle, the inner and
outer medullary areas, glomeruli, and cultured mesangial cells
have all been found to contain specific, high affinity receptors
for ANP [5, 26]. ANP-receptor binding is not inhibited by
angiotensin II (All) or other vasoactive peptides [26—291. The
functional importance of these receptors is suggested by the
findings of Appel et al [30] that the synthetic ANF analog,
atriopeptin III, directly inhibited All-induced contraction of
cultured mesangial cells. In addition, Fried et al [15] reported
that sANP directly increased glomerular capillary permeability
as well as hydrostatic pressure in the isolated, in vitro perfused
dog glomerulus. Implicit in these observations is the possibility
that binding of ANP to mesangial receptors might enhance
post-ischemic glomerular permeability by attenuating vasoac-
tive peptide-mediated mesangial contraction [31—34]. ANP has
also been found to produce glomerular capillary hemodynamic
changes consistent with afferent vasodilatation and efferent
vasoconstriction with consequent increase in glomerular capil-
lary hydrostatic pressure [15, 171.
The ameliorative effect of sANP on renal autograft function
observed in the current study was associated with a significant
increase in total renal blood flow. Clinical and experimental
studies have demonstrated that initial dysfunction of both renal
autografts and allografts is associated with cortical and outer
medullary hypoperfusion which resolves with recovery of pres-
ervation-related ischemic injury and treatment of acute rejec-
tion, respectively [35—37]. In contrast, intrarenal vasodilatation
has been found to occur with administration of atrial extract in
the isolated, perfused rat kidney following vasoconstriction
produced by pretreatment with All and other vasoactive pep-
tides [II]. sANP reverses vascular smooth muscle contraction
20
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(Pre-vehicle) (Vehicle)
induced by All and other vasoactive peptides and suppresses
renin secretion, particularly in states characterized by stimula-
tion of the renin-angiotensin system (such as, following acute
ischemic injury) [8, 38, 39]. Experimental studies have also
shown a relaxation effect of ANP on renal arcuate arteries [29]
and a dose-dependent increase in renal blood flow in response
to administration of sANP in conscious dogs [7]. In addition,
ANP has been reported to increase perfusion of the juxtamed-
ullary area [13, 14] where, following ischemic injury, regional
blood flow may remain compromised after return of total renal
blood flow to control values [40, 41]. This effect might also be
expected to promote proximal tubular recovery from ischemic
injury [40, 42].
The mechanisms by which administration of supraphysio-
logic quantities of sANP confer protection from cold ischemic
injury might also be expected to ameliorate both acute cyclos-
porine nephrotoxic and acute immunologic functional renal
injuries [36, 37, 43, 44]. Indeed, a protective effect of sANP
Fig. 6. Effect of ANP on renal blood flow
Period II rate, /5 24-hour cold ischemia. A. Control
(ANP) group. B. Experimental group.
Fig. 7. Effect of ANP on systemic blood
Period II pressure (systolic). A. Control group. B.
(ANP) Experimental group.
administration versus acute CsA nephrotoxicity has been re-
ported in the rat [45—47]. The present data, as well as the studies
cited above, support further investigation of the therapeutic
potential of synthetic atriopeptins for ameliorating initial renal
allograft dysfunction in the setting of clinical transplantation.
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